Amarin to Report Fourth Quarter and Full Year 2021 Financial Results And Host Conference Call on March 1, 2022
Amarin Corporation plc (NASDAQ: AMRN) announced a conference call with senior management to discuss its fourth quarter and full year 2021 financial results on March 1, 2022, at 8:00 a.m. ET. This call will follow the release of the financial results earlier that day. Investors can access the call through the company’s investor relations website or by dialing in. Amarin focuses on cardiovascular disease management and aims to advance treatment beyond traditional therapies. The replay will be available for two weeks post-call.
- Conference call scheduled to discuss Q4 and full year 2021 financial results, indicating transparency and engagement with investors.
- None.
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company's fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022 at 8:00 a.m. ET. The conference call will follow the anticipated release of the Company's financial results earlier that day.
Conference Call and Webcast Information:
Access to live call:
Go to the investor relations section of the Company's website at www.amarincorp.com
Dial in with in the United States: 888-506-0062
International dial in: 973-528-0011
Access Code 424818
Access to replay:
Dial in within the United States: 877-481-4010
International dial in: 919-882-2331
Access Code 44616
The replay of the call will also be available through the Company's website shortly after the call and be made available for a period of two weeks.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor Inquiries:
Lisa DeFrancesco
Amarin Corporation plc
IR@amarincorp.com (investor inquiries)
Media Inquiries: Communications
Amarin Corporation plc
PR@amarincorp.com (media inquiries)
FAQ
When will Amarin Corporation announce its Q4 and full year 2021 financial results?
How can I access the Amarin Corporation financial results conference call?
What time is the Amarin Corporation conference call on March 1, 2022?
What is the purpose of the Amarin Corporation conference call?
